Medicines List

The product has not yet been released on the market.

Description

Calisa contains two active ingredients, bisoprolol fumarate and ramipril in one capsule:
Ramipril is an angiotensin converting enzyme (ACE) inhibitor. It works by widening the blood vessels, which makes it easier for your heart to pump blood through them.
Bisoprolol fumarate belongs to a group of medicine called beta-blockers. Beta-blockers slow down the heart rate and make the heart more efficient at pumping blood around the body.

Indications

Calisa is used to treat high blood pressure (hypertension) and/or chronic heart failure with left heart chamber dysfunction (a condition where the heart is unable to pump enough blood to meet the body’s needs resulting in breathlessness and swelling) and/or to reduce the risk of cardiac events, such as heart attack, in patients with chronic coronary artery disease (a condition where the blood supply to the heart is reduced or blocked) and who have already had a heart attack and/or an operation to improve the blood supply to the heart by widening the vessels that supply it, or diabetes with at least one cardiovascular risk factor.

 Subject to medical prescription.

 Concentration and pharmaceutical form: 5 mg/2.5 mg; 5 mg/5 mg; 10 mg/5 mg; 10 mg/10 mg hard capsules

The product has not yet been released on the market.

Description

Eltrombopag Tchaikapharma contains eltrombopag, which belongs to a group of medicines called thrombopoietin-receptor antagonists. It is used to help increase the number of platelets in your blood. Platelets are blood cells that help to reduce or prevent bleeding.

Indications

Eltrombopag Tchaikapharma is used to treat a bleeding disorder called immune (primary) thrombocytopenia (ITP) in patients aged 1 year and above who have already taken other medicines (corticosteroids or immunoglobulins), which have not worked.

Eltrombopag Tchaikapharma can also be used to treat low platelet count (thrombocytopenia) in adults with hepatitis C virus (HCV) infections, if they have had problems with side effects while on interferon treatment.

Subject to medical prescription.

Concentration and pharmaceutical form: 25 mg film-coated tablets

Description

Tadalafil-Tchaikapharma contains the active substance tadalafil, which belongs to a group of medicines known as phosphodiesterase type 5 inhibitors. Tadalafil improves blood flow by relaxing the smooth muscle of blood vessels. This results in improved erectile function and relief of urinary symptoms associated with benign prostatic hyperplasia. Tadalafil Tchaikapharma is not intended for use in women.

Indications

Tadalafil-Tchaikapharma is indicated in adult men for:

• treatment of erectile dysfunction, characterized by the inability to achieve or maintain an erection sufficient for sexual activity;
• treatment of urinary symptoms associated with benign prostatic hyperplasia, such as difficulty in urination, sensation of incomplete bladder emptying and increased frequency of urination, including during the night.

Subject to medical prescription.

Concentration and pharmaceutical form: 5 mg; 10 mg; 20 mg film-coated tablets

The product has not yet been released on the market.

Description

Linagliptin/Metformin Tchaikapharma contains the active substances linagliptin and metformin and belongs to the group of medicines used for the treatment of type 2 diabetes mellitus. Linagliptin increases insulin secretion and reduces blood glucose levels, while metformin decreases glucose production in the body and improves insulin sensitivity. Their combined action helps to achieve effective blood glucose control.

Indications

Linagliptin/Metformin Tchaikapharma is indicated in adult patients with type 2 diabetes mellitus as an adjunct to diet and exercise to improve glycemic control:

• in patients who have not achieved adequate glycemic control with the maximum tolerated dose of metformin administered as monotherapy;
• in combination with other medicinal products for the treatment of diabetes, including insulin, in patients who have not achieved adequate glycemic control with metformin and these medicinal products;
• in patients already treated with a combination of linagliptin and metformin administered as separate tablets.

Subject to medical prescription.

Concentration and pharmaceutical form: 2,5 mg /850 mg; 2,5 mg /1000 mg film-coated tablets